UBS Group’s Lichen China LICN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $985 | Sell |
167
-73
| -30% | -$240 | ﹤0.01% | 9666 |
|
|
2025
Q4 | $677 | Sell |
240
-4,106
| -94% | -$14.8K | ﹤0.01% | 9849 |
|
|
2025
Q3 | $19K | Sell |
4,346
-2,705
| -38% | -$12.1K | ﹤0.01% | 8183 |
|
|
2025
Q2 | $29.1K | Buy |
7,051
+6,704
| +1,932% | +$28.5K | ﹤0.01% | 8181 |
|
|
2025
Q1 | $1.34K | Sell |
347
-829
| -70% | -$12.8K | ﹤0.01% | 9534 |
|
|
2024
Q4 | $41.9K | Buy |
1,176
+1,083
| +1,165% | +$319K | ﹤0.01% | 7403 |
|
|
2024
Q3 | $33.6K | Sell |
93
-38
| -29% | -$14.6K | ﹤0.01% | 7067 |
|
|
2024
Q2 | $38.2K | Buy |
+131
| New | +$33.6K | ﹤0.01% | 6895 |
|
|
2024
Q1 | – | Sell |
-3
| Closed | -$1.3K | – | 9720 |
|
|
2023
Q4 | $1.3K | Sell |
3
-8
| -73% | -$2.42K | ﹤0.01% | 8346 |
|
|
2023
Q3 | $2.66K | Sell |
11
-16
| -59% | -$3.32K | ﹤0.01% | 7667 |
|
|
2023
Q2 | $7.15K | Buy |
27
+10
| +59% | +$4.17K | ﹤0.01% | 7319 |
|
|
2023
Q1 | $7.31K | Buy |
+17
| New | +$7.96K | ﹤0.01% | 7818 |
|
UBS Group's LICN Position: Q1 2026 in Review
UBS Group reduced its Lichen China (LICN) stake by 30% in Q1 2026, selling an estimated $240 and leaving 167 shares worth $985. The position accounts for ﹤0.01% of the portfolio, ranked #9666.
UBS Group first reported a position in LICN in Q1 2023 and has held it in 12 quarters since. The position peaked at $41.9K in Q4 2024. 1 fund tracked by Wall St. Rank holds LICN as of Q1 2026.
- UBS Group held 167 shares of Lichen China worth $985 as of Q1 2026.
- UBS Group sold 73 Lichen China shares in Q1 2026, an estimated $240.
- Lichen China made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9666 holding.
- UBS Group first reported a position in Lichen China in Q1 2023 and has held it in 12 quarters since.
- UBS Group's Lichen China position peaked at $41.9K in Q4 2024.
- 1 fund tracked by Wall St. Rank held Lichen China as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.